AstraZeneca PLC (LSE:AZN) - Share price - Overview

Not a customer yet?

Buy shares from £4.95 with our easy-to-use SIPPs, ISAs and Dealing accounts

Find out more

Stock Report

AstraZeneca PLC AZN

Last Price
GBX4,960.50

Day Change
90.50|1.86%

As of 13/11/2017
11:09:36 GMT | GBX
Minimum 15 Minutes Delay.

Last Close4,870.00p
Day Range4,910.00 - 5,004.00
Mkt Cap61.65Bil
52-Wk Range3,996.00 - 5,520.00
Yield %4.03
ISINGB0009895292
Volume550,866
P/E25.91
P/S3.68
P/CF19.77

Share Price

Total Returns 10/11/2017

 Chg (%)  
More ...
AstraZeneca PLC-5.77 
FTSE 100 TR GBP-1.12
 
Financials
201420152016
More ...
Income Statement
Turnover16,124.3816,172.1317,039.88
Operating Profit1,297.992,692.743,631.40
Net Profit750.131,849.702,523.17
Reported EPS59.52145.96204.46
Balance Sheet
Current Assets10,708.2910,860.2710,732.80
Non Current Assets26,870.4429,885.9339,868.86
Total Assets37,578.7340,746.1950,601.67
Current Liabilities11,114.2510,088.1712,346.53
Total Liabilities24,979.1628,188.3937,111.61
Total Equity12,599.5712,557.8013,490.06
Cash Flow
Operating Cash Flow5,340.173,386.543,877.35
Net Change in Cash-1,627.20-24.22-850.44
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
20174,094.98282.3547.4617.250.36212.984.37
20184,701.90307.698.9815.831.76213.844.39

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
More ...
27/07/2017PurchasePhilip Broadley4,282.002,30098,486.00
28/03/2017Transfer inMr. Pascal Soriot0.00115,7930.00
28/03/2017Transfer inMr. Marc Dunoyer0.0026,8970.00
16/12/2016Transfer OutMr. Pascal Soriot0.0056,9510.00

Company Profile

AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.

Sector

Drug Manufacturers - Major

Market Position

8 of 1833 Companies

Index

FTSE 100 ,FTSE 350 ,FTSE Eurotop 100 ,S&P Europe 350 ,Eurotop 300

Outlook

(09/11/2017) ceo - "Our financial performance in the quarter was in line with expectations, reflecting good commercial execution, including strong growth in Emerging Markets with standout sales in China"

Next Event 31/12/2017

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)16.0113.656.39
Div Yld (E)4.394.184.24
PEG (E)1.250.981.58
ROCE496.29177.83179.87
Op Mrgn17.19-9.37-105.26
EPS Grwth12.7914.5413.79
Dividends
PreviousLatest
More ...
Record Date17/02/1711/08/17
Ex-Div16/02/1710/08/17
Paid20/03/1711/09/17
Amnt150.2068.90

Broker Sentiment

Strong Buy0
Buy3
Hold0
Sell1
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. Leif Johansson
Chief Executive OfficerMr. Pascal Soriot
Chief Financial OfficerMr. Marc Dunoyer
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.